When is LEXX's latest earnings report released?
The most recent financial report for Lexaria bioscience corp. (LEXX) covers the period of 2026Q2 and was published on 2026/02/28. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LEXX's short-term business performance and financial health. For the latest updates on LEXX's earnings releases, visit this page regularly.
What is the operating profit of LEXX?
According to the latest financial report, Lexaria bioscience corp. (LEXX) reported an Operating Profit of -1.45M with an Operating Margin of -7,259.52% this period, representing a growth of 47.22% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is LEXX's revenue growth?
In the latest financial report, Lexaria bioscience corp. (LEXX) announced revenue of 20K, with a Year-Over-Year growth rate of -88.51%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does LEXX have?
At the end of the period, Lexaria bioscience corp. (LEXX) held Total Cash and Cash Equivalents of 5.13M, accounting for 0.79 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does LEXX go with three margins increasing?
In the latest report, Lexaria bioscience corp. (LEXX) did not achieve the “three margins increasing” benchmark, with a gross margin of -32.84%%, operating margin of -7,259.52%%, and net margin of -7,249.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LEXX's profit trajectory and future growth potential.
Is LEXX's EPS continuing to grow?
According to the past four quarterly reports, Lexaria bioscience corp. (LEXX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of LEXX?
Lexaria bioscience corp. (LEXX)'s Free Cash Flow (FCF) for the period is -2.22M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 48.19% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of LEXX?
The latest valuation data shows Lexaria bioscience corp. (LEXX) has a Price-To-Earnings (PE) ratio of -2.95 and a Price/Earnings-To-Growth (PEG) ratio of 0.15. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
